Meta-analysis of the relationship between p21 Ser31Arg polymorphism and lung cancer susceptibility

Genetics and Molecular Research

Volumn 10, Issue 4, 2011, Pages 2449-2456

  Lin, G ^a   Fang, F ^a   Yu, X J ^a   Yu, L ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Lung cancer risk; Meta analysis; P21; Polymorphism; Ser31Arg

Indexed keywords

ARGININE; PROTEIN P21; SERINE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; DNA POLYMORPHISM; ETHNICITY; EXPLORATORY RESEARCH; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEREDITY; HIGH RISK POPULATION; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; META ANALYSIS (TOPIC); P21 GENE; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; AMINO ACID SUBSTITUTION; FEMALE; GENETIC POLYMORPHISM; GENETICS; LUNG TUMOR; MALE; META ANALYSIS;

AMINO ACID SUBSTITUTION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 84856427517     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2011.October.13.2     Document Type: Article

References (16)

1. Abbas T and Dutta A (2009). p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9: 400-414.
2. Chedid M, Michieli P, Lengel C, Huppi K, et al. (1994). A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9: 3021-3024.
3. Choi YY, Kang HK, Choi JE, Jang JS, et al. (2008). Comprehensive assessment of P21 polymorphisms and lung cancer risk. J. Hum. Genet. 53: 87-95.
4. DerSimonian R and Laird N (1986). Meta-analysis in clinical trials. Control Clin. Trials 7: 177-188.
5. Egger M, Davey SG, Schneider M and Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
6. Harada K and Ogden GR (2000). An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 36: 3-7.
7. Hsia TC, Chiang HC, Chiang D, Hang LW, et al. (2003). Prediction of survival in surgical unresectable lung cancer by artificial neural networks including genetic polymorphisms and clinical parameters. J. Clin. Lab. Anal. 17: 229-234.
8. Kiyohara C, Otsu A, Shirakawa T, Fukuda S, et al. (2002). Genetic polymorphisms and lung cancer susceptibility: a review. Lung Can. 37: 241-256.
9. Lau J, Ioannidis JP and Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127: 820-826.
10. Mantel N and Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22: 719-748.
11. Mitsudomi T (2010). Advances in target therapy for lung cancer. Jpn. J. Clin. Oncol. 40: 101-106.
12. Popanda O, Edler L, Waas P, Schattenberg T, et al. (2007). Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55: 25-34.
13. Shih CM, Lin PT, Wang HC, Huang WC, et al. (2000). Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn. J. Cancer Res. 91: 9-15.
14. Sjalander A, Birgander R, Rannug A, Alexandrie AK, et al. (1996). Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum. Hered. 46: 221-225.
15. Su L, Liu G, Zhou W, Xu LL, et al. (2003). No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk. Cancer Epidem. Biomar. Prev. 12: 174-175.
16. Xiong Y, Hannon GJ, Zhang H, Casso D, et al. (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.